Pharmacoeconomic Analysis of Hemophilia Care in Romania

Hemophilia, a congenital X linked disease, has the serious burden of bleeding, requiring life-long replacement with coagulation factors (CF). In the present day, there is a continuously improving treatment for this condition. Objective: Our observational, cross-sectional study aims at finding out wh...

Full description

Saved in:
Bibliographic Details
Published in:Processes 2020-12, Vol.8 (12), p.1676
Main Authors: Serban, Petre, Vlaicu, Brigitha, Serban, Margit, Ursu, Cristina Emilia, Traila, Adina, Jinca, Cristian, Patrascu, Jenel Marian, Andrei, Daniel, Kozma, Andrei, Arghirescu, Teodora Smaranda
Format: Article
Language:English
Subjects:
Bleeding
Coagulation
Cost analysis
Economics
Genotype & phenotype
Hemophilia
Life expectancy
Patients
Pharmacology
Prophylaxis
Quality of life
Questionnaires
Subgroups
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hemophilia, a congenital X linked disease, has the serious burden of bleeding, requiring life-long replacement with coagulation factors (CF). In the present day, there is a continuously improving treatment for this condition. Objective: Our observational, cross-sectional study aims at finding out whether a prophylactic replacement with CF is affordable from the point of view of its cost-effectiveness in our country. Material and methods: A cohort of 122 persons with hemophilia were included in this patient-reported outcome survey, and they answered a questionnaire consisting of 56 items, focused on 4 domains—socio-demographic, medical, quality of health/life and cost/cost-effectiveness. Results and discussion: The markers for quality of health/life were correlated with the direct and indirect costs of care, comparing subgroup 1 of patients with prophylactic vs. subgroup 2 with on-demand replacement. Based on the incremental quality adjusted life years and the incremental costs, we calculated the incremental cost-effectiveness ratio (ICER) proving that prophylaxis is more cost-effective than on-demand replacement on a long time basis. Conclusions: The ICER is a threshold recommending the reimbursement of costs for a life-long prophylactic replacement in our country.
ISSN:2227-9717
2227-9717
DOI:10.3390/pr8121676